Loncastuximab tesirine
Loncastuximab Tesirine[edit]
Loncastuximab tesirine is an antibody-drug conjugate (ADC) used in the treatment of certain types of cancer, specifically B-cell lymphoma. It is a targeted therapy that combines a monoclonal antibody with a cytotoxic drug, allowing for the selective delivery of the drug to cancer cells.
Mechanism of Action[edit]
Loncastuximab tesirine works by targeting the CD19 antigen, which is commonly expressed on the surface of B-cell malignancies. The monoclonal antibody component of the ADC binds to CD19, facilitating the internalization of the conjugate into the cancer cell. Once inside, the cytotoxic agent, a pyrrolobenzodiazepine (PBD) dimer, is released, leading to DNA cross-linking and ultimately inducing cell death.
Clinical Use[edit]
Loncastuximab tesirine is primarily used in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and other B-cell non-Hodgkin lymphomas. It is typically administered to patients who have not responded to other forms of treatment, such as chemotherapy or immunotherapy.
Administration[edit]
The drug is administered via intravenous infusion, with the dosage and schedule determined by the patient's specific condition and response to treatment. Patients receiving loncastuximab tesirine are monitored for potential side effects, which can include hematologic toxicity, liver enzyme elevations, and infusion-related reactions.
Side Effects[edit]
Common side effects of loncastuximab tesirine include fatigue, nausea, and thrombocytopenia. More serious adverse effects can occur, such as neutropenia, anemia, and hepatotoxicity. Patients are advised to report any unusual symptoms to their healthcare provider promptly.
